Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC is a phase 1/2, interventional study registered as NCT07718243 by Institute of Cancer Research, United Kingdom, with a registry enrolment figure of 62 participants, started 2026-08-28 and due to reach its primary completion in 2030-01-31. Interventions recorded: Bexmarilimab 1mg/kg and nivolumab 1mg/kg; Bexmarilimab 3mg/kg and nivolumab 1mg/kg; Recommended Phase II Dose. Conditions listed: Melanoma (Skin Cancer); Non Small Cell Lung Cancer; Solid Tumor in Advanced Stage. Primary outcome: To establish a recommended Phase II dose (RP2D) of bexmarilimab in combination with nivolumab; Determining causality of each adverse event to bexmarilimab and nivolumab and grading severity according to the NCI CTCAE Version 5.0; Evaluation of disease response by RECIST criteria version 1.1, immune-. Lung eligibility wording from the registry: "Part B1: Histologically proven NSCLC". Sites: United Kingdom. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.